Publications by authors named "Mine Camlibel"

Objectives: This study was conducted to examine the dose-related effects over time of oleuropein on the proliferation and area of tumor spheroids in hepatocellular carcinoma cells.

Materials And Methods: We examined the possible effects of 100 to 500 μM dose concentrations of oleuropein on HepG2 cell proliferation using a real-time cell analyzer. A 3-dimensional hepatocellular carcinoma tumor spheroid model was established by seeding HepG2 cells at a density of 160 cells/well in custom 96-well microplates with low attachment surfaces and culturing for 3 days.

View Article and Find Full Text PDF

Background: Anemia is an important predictor of mortality and morbidity in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD). Erythropoietin (EPO) is an expensive drug, which increases the cost of therapy. In addition, anemia persists in 20-30% of cases despite EPO treatment.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Mine Camlibel"

  • - Mine Camlibel's recent research investigates the effectiveness of oleuropein on the proliferation of hepatocellular carcinoma cells, utilizing a three-dimensional tumor spheroid model to assess dose-related effects over time.
  • - The study in 'Exp Clin Transplant' rigorously evaluates the impact of varying concentrations of oleuropein (100 to 500 μM) on HepG2 cell growth, revealing significant insights into potential therapeutic applications.
  • - Earlier research by Camlibel focused on the impact of high-flux hemodialysis on renal anemia in end-stage renal disease patients, highlighting the challenges of managing anemia even with erythropoietin treatment and the associated healthcare costs.